WO1996019200A1 - Preparation granulaire a liberation prolongee et procede de production - Google Patents
Preparation granulaire a liberation prolongee et procede de production Download PDFInfo
- Publication number
- WO1996019200A1 WO1996019200A1 PCT/JP1995/002594 JP9502594W WO9619200A1 WO 1996019200 A1 WO1996019200 A1 WO 1996019200A1 JP 9502594 W JP9502594 W JP 9502594W WO 9619200 A1 WO9619200 A1 WO 9619200A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained
- plasticizer
- polymer
- granular preparation
- temperature
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Definitions
- the amount of the plasticizer to be added is preferably such that the MFT or Tg of the mixture of the plasticizer and the above polymer is about 100 ° C. or less, particularly preferably 90 ° C. or less.
- the amount is preferably 0.01 to 5 parts by weight, more preferably 0.01 to 1 part by weight, based on the polymer.
- Granulated granules were prepared in the same manner as in Example 1, and the granules obtained by drying the granules in 1, 2 or 3 hours and the granules (control) obtained by drying at room temperature for 24 hours were used. A dissolution test similar to that of Example 1 was performed for those having a thickness of 0 to 1400 zm, and the effect of drying time was examined. Table 4 shows the results.
- the formulations having the formulations shown in Table 1 were manufactured by slightly changing the manufacturing method of Example 13 and the sustained release properties were examined.
- polysorbate 80 was dissolved in water 5, and triethyl citrate was uniformly suspended therein to obtain a suspension.
- the suspension was slowly dropped into the mixture and kneaded.
- the kneaded product and water 3 were kneaded in a kneader.
- the obtained kneaded product was granulated by an extrusion granulator (a screen with a mesh of 0.8 mm), and then passed through a marmellaizer to obtain granules.
- the release rate could be controlled by adding a water-soluble substance, hydroxypropylcellulose, to the granules.
- granular preparations were prepared as follows, and their sustained-release properties were examined. First, triethyl citrate was suspended in water 6 to obtain a suspension. Next, theophylline and ethylcellulose were mixed in a high-speed stirring granulator, and the mixture was kneaded while slowly dripping the suspension. Next, the kneaded product, water 4, was put into a kneader and kneaded. The obtained kneaded product was granulated with an extrusion granulator (a screen having a mesh of 0.5 mm), and then passed through a marmellaizer to obtain granules.
- an extrusion granulator a screen having a mesh of 0.5 mm
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95940461A EP0797987B1 (en) | 1994-12-19 | 1995-12-18 | Sustained-release granular preparation and process for producing the same |
DE69531957T DE69531957T2 (de) | 1994-12-19 | 1995-12-18 | Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung |
CA002207334A CA2207334C (en) | 1994-12-19 | 1995-12-18 | Sustained-release granular preparations and production process thereof |
AT95940461T ATE251896T1 (de) | 1994-12-19 | 1995-12-18 | Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung |
JP51966196A JP3893439B2 (ja) | 1994-12-19 | 1995-12-18 | 徐放性粒状製剤およびその製造方法 |
DK95940461T DK0797987T3 (da) | 1994-12-19 | 1995-12-18 | Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf |
US08/849,457 US5858411A (en) | 1994-12-19 | 1995-12-18 | Sustained-release granular preparations and production process thereof |
FI972622A FI119720B (fi) | 1994-12-19 | 1997-06-18 | Pitkävaikutteisten rakeisten valmisteiden valmistusmenetelmä |
NO19972814A NO320356B1 (no) | 1994-12-19 | 1997-06-18 | Fremgangsmate for fremstilling av et matrikstype-medisinsk forlenget-frigjoring granulaert preparater |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/314414 | 1994-12-19 | ||
JP31441494 | 1994-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996019200A1 true WO1996019200A1 (fr) | 1996-06-27 |
Family
ID=18053063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/002594 WO1996019200A1 (fr) | 1994-12-19 | 1995-12-18 | Preparation granulaire a liberation prolongee et procede de production |
Country Status (14)
Country | Link |
---|---|
US (2) | US5858411A (ja) |
EP (1) | EP0797987B1 (ja) |
JP (1) | JP3893439B2 (ja) |
KR (1) | KR100424931B1 (ja) |
CN (1) | CN1093758C (ja) |
AT (1) | ATE251896T1 (ja) |
DE (1) | DE69531957T2 (ja) |
DK (1) | DK0797987T3 (ja) |
ES (1) | ES2210321T3 (ja) |
FI (1) | FI119720B (ja) |
NO (1) | NO320356B1 (ja) |
PT (1) | PT797987E (ja) |
TW (1) | TW406022B (ja) |
WO (1) | WO1996019200A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000229886A (ja) * | 1999-02-09 | 2000-08-22 | Pfizer Prod Inc | 優れた生物学的利用能を持つ塩基性薬剤組成物 |
JP2002514600A (ja) * | 1998-05-09 | 2002-05-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ガチフロキサシン又はその薬学的に使用可能な塩又は水和物を含有する、再現可能な有効物質放出を伴う経口用薬剤 |
JP2007500699A (ja) * | 2003-07-31 | 2007-01-18 | ザノダイン ファーマシューティカルズ,インコーポレーテッド | 副作用が低減されたトラネキサム酸製剤 |
JP2008508275A (ja) * | 2004-07-30 | 2008-03-21 | ザノダイン ファーマシューティカルズ,インコーポレーテッド | トラネキサム酸製剤 |
US7947739B2 (en) | 2004-03-04 | 2011-05-24 | Ferring B.V. | Tranexamic acid formulations |
US8022106B2 (en) | 2004-03-04 | 2011-09-20 | Ferring B.V. | Tranexamic acid formulations |
US8273795B2 (en) | 2004-03-04 | 2012-09-25 | Ferring B.V. | Tranexamic acid formulations |
US8957113B2 (en) | 2004-03-04 | 2015-02-17 | Ferring B.V. | Tranexamic acid formulations |
JP5870023B2 (ja) * | 2010-02-22 | 2016-02-24 | 第一三共株式会社 | 経口用徐放性固形製剤 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
EP0901786B1 (en) | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
US6632455B2 (en) * | 1997-12-22 | 2003-10-14 | Schering Corporation | Molecular dispersion composition with enhanced bioavailability |
JP4472184B2 (ja) | 1998-09-30 | 2010-06-02 | ビーエーエスエフ ソシエタス・ヨーロピア | 医薬投与剤形においてコーティング剤、結合剤および/またはフィルム形成助剤として使用される水溶性または水分散性のポリエーテル含有重合物の適用 |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
GB0003782D0 (en) * | 2000-02-17 | 2000-04-05 | Dumex Ltd As | Process |
JP4310605B2 (ja) * | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
US20090214644A1 (en) * | 2003-07-31 | 2009-08-27 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations with reduced adverse effects |
US20050245614A1 (en) * | 2004-03-04 | 2005-11-03 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
US20060275365A1 (en) * | 2005-06-07 | 2006-12-07 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
US20070059359A1 (en) * | 2005-06-07 | 2007-03-15 | Thomas Backensfeld | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof |
US20070082048A1 (en) * | 2005-06-08 | 2007-04-12 | Ronald Warner | Sleep aid formulations |
AU2006262386B2 (en) | 2005-06-20 | 2012-02-02 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use |
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
EP2001445B1 (en) * | 2006-03-16 | 2014-07-23 | Euro-Celtique S.A. | Pharmaceutical spheroids |
KR101697773B1 (ko) * | 2008-03-10 | 2017-01-18 | 유로드러그 레버러토리즈 비. 브이. | 독소필린을 포함하는 변형 방출 조성물 |
US20100280117A1 (en) * | 2009-04-30 | 2010-11-04 | Xanodyne Pharmaceuticals, Inc. | Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders |
US20110184060A1 (en) * | 2010-01-22 | 2011-07-28 | Xenoport, Inc. | Oral dosage forms having a high loading of a tranexamic acid prodrug |
GB201010083D0 (en) * | 2010-06-16 | 2010-07-21 | Univ Bradford | Compositions and methods |
KR102286952B1 (ko) * | 2013-12-31 | 2021-08-09 | 롯데정밀화학 주식회사 | 입도분포가 조절된 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트(hpmcas) 입자의 제조방법 및 hpmcas 분말 |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
RU2018145364A (ru) | 2016-06-27 | 2020-07-28 | Ачиллион Фармасьютикалс, Инк. | Хиназолиновые и индольные соединения для лечения медицинских нарушений |
JP2021535112A (ja) | 2018-08-20 | 2021-12-16 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体d因子の医学的障害の治療のための医薬化合物 |
EP3866773A4 (en) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02503315A (ja) * | 1987-11-24 | 1990-10-11 | ボード オブ リージエンツ オブ ザ ユニバーシテイ オブ テキサス システム | 機能的に活性な組成物の徐放性を有する固体形態物の製造法 |
JPH0558880A (ja) * | 1991-02-15 | 1993-03-09 | Dai Ichi Seiyaku Co Ltd | マスクされた粒状物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4330338A (en) * | 1978-10-02 | 1982-05-18 | Purdue Research Foundation | Pharmaceutical coating composition, and preparation and dosages so coated |
US4329451A (en) * | 1980-11-03 | 1982-05-11 | The Dow Chemical Company | Preparing an aqueous dispersion of colloidal size particles of a water-insoluble polysaccharide derivative |
JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
JPS6143108A (ja) * | 1984-08-03 | 1986-03-01 | Nippon Shinyaku Co Ltd | 医薬品製剤及びその製造法 |
LU86099A1 (fr) * | 1985-09-30 | 1987-04-02 | Pharlyse | Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant |
US5051261A (en) * | 1987-11-24 | 1991-09-24 | Fmc Corporation | Method for preparing a solid sustained release form of a functionally active composition |
US4835188A (en) * | 1987-12-08 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
US4916161A (en) * | 1988-10-25 | 1990-04-10 | Bristol-Myers Squibb | Taste-masking pharmaceutical agents |
US5326572A (en) * | 1989-03-23 | 1994-07-05 | Fmc Corporation | Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions |
EP0421582A1 (en) * | 1989-10-03 | 1991-04-10 | Warner-Lambert Company | Chewable spray dried spheroidal microcapsules and polymer coated microcapsules and method for preparing same |
JPH03232814A (ja) * | 1990-02-08 | 1991-10-16 | Shin Etsu Chem Co Ltd | 徐放性錠剤の製造方法 |
ATE159426T1 (de) * | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
DE4244466C2 (de) * | 1992-12-24 | 1995-02-23 | Pharmatech Gmbh | Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten |
-
1995
- 1995-12-18 AT AT95940461T patent/ATE251896T1/de not_active IP Right Cessation
- 1995-12-18 ES ES95940461T patent/ES2210321T3/es not_active Expired - Lifetime
- 1995-12-18 KR KR1019970703851A patent/KR100424931B1/ko not_active IP Right Cessation
- 1995-12-18 JP JP51966196A patent/JP3893439B2/ja not_active Expired - Fee Related
- 1995-12-18 DE DE69531957T patent/DE69531957T2/de not_active Expired - Lifetime
- 1995-12-18 PT PT95940461T patent/PT797987E/pt unknown
- 1995-12-18 EP EP95940461A patent/EP0797987B1/en not_active Expired - Lifetime
- 1995-12-18 DK DK95940461T patent/DK0797987T3/da active
- 1995-12-18 TW TW084113515A patent/TW406022B/zh not_active IP Right Cessation
- 1995-12-18 CN CN95196885A patent/CN1093758C/zh not_active Expired - Fee Related
- 1995-12-18 WO PCT/JP1995/002594 patent/WO1996019200A1/ja active IP Right Grant
- 1995-12-18 US US08/849,457 patent/US5858411A/en not_active Expired - Lifetime
-
1997
- 1997-06-18 FI FI972622A patent/FI119720B/fi active IP Right Grant
- 1997-06-18 NO NO19972814A patent/NO320356B1/no not_active IP Right Cessation
-
1998
- 1998-06-11 US US09/095,661 patent/US6030644A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02503315A (ja) * | 1987-11-24 | 1990-10-11 | ボード オブ リージエンツ オブ ザ ユニバーシテイ オブ テキサス システム | 機能的に活性な組成物の徐放性を有する固体形態物の製造法 |
JPH0558880A (ja) * | 1991-02-15 | 1993-03-09 | Dai Ichi Seiyaku Co Ltd | マスクされた粒状物 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514600A (ja) * | 1998-05-09 | 2002-05-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ガチフロキサシン又はその薬学的に使用可能な塩又は水和物を含有する、再現可能な有効物質放出を伴う経口用薬剤 |
JP2000229886A (ja) * | 1999-02-09 | 2000-08-22 | Pfizer Prod Inc | 優れた生物学的利用能を持つ塩基性薬剤組成物 |
JP2007500699A (ja) * | 2003-07-31 | 2007-01-18 | ザノダイン ファーマシューティカルズ,インコーポレーテッド | 副作用が低減されたトラネキサム酸製剤 |
US8968777B2 (en) | 2003-07-31 | 2015-03-03 | Ferring B.V. | Tranexamic acid formulations with reduced adverse effects |
JP2011093938A (ja) * | 2003-07-31 | 2011-05-12 | Ferring Bv | 副作用が低減されたトラネキサム酸製剤 |
US8273795B2 (en) | 2004-03-04 | 2012-09-25 | Ferring B.V. | Tranexamic acid formulations |
US8022106B2 (en) | 2004-03-04 | 2011-09-20 | Ferring B.V. | Tranexamic acid formulations |
US7947739B2 (en) | 2004-03-04 | 2011-05-24 | Ferring B.V. | Tranexamic acid formulations |
US8487005B2 (en) | 2004-03-04 | 2013-07-16 | Ferring B.V. | Tranexamic acid formulations |
US8791160B2 (en) | 2004-03-04 | 2014-07-29 | Ferring B.V. | Tranexamic acid formulations |
US8809394B2 (en) | 2004-03-04 | 2014-08-19 | Ferring B.V. | Tranexamic acid formulations |
US8957113B2 (en) | 2004-03-04 | 2015-02-17 | Ferring B.V. | Tranexamic acid formulations |
US9060939B2 (en) | 2004-03-04 | 2015-06-23 | Ferring B.V. | Tranexamic acid formulations |
JP2011168596A (ja) * | 2004-07-30 | 2011-09-01 | Ferring Bv | トラネキサム酸製剤 |
JP2014193878A (ja) * | 2004-07-30 | 2014-10-09 | Ferring Bv | トラネキサム酸製剤 |
JP2008508275A (ja) * | 2004-07-30 | 2008-03-21 | ザノダイン ファーマシューティカルズ,インコーポレーテッド | トラネキサム酸製剤 |
JP5870023B2 (ja) * | 2010-02-22 | 2016-02-24 | 第一三共株式会社 | 経口用徐放性固形製剤 |
Also Published As
Publication number | Publication date |
---|---|
DE69531957D1 (de) | 2003-11-20 |
JP3893439B2 (ja) | 2007-03-14 |
EP0797987A4 (en) | 1998-09-09 |
NO972814L (no) | 1997-08-18 |
EP0797987B1 (en) | 2003-10-15 |
ATE251896T1 (de) | 2003-11-15 |
DE69531957T2 (de) | 2004-08-12 |
FI119720B (fi) | 2009-02-27 |
FI972622A (fi) | 1997-06-18 |
NO972814D0 (no) | 1997-06-18 |
FI972622A0 (fi) | 1997-06-18 |
US5858411A (en) | 1999-01-12 |
TW406022B (en) | 2000-09-21 |
US6030644A (en) | 2000-02-29 |
PT797987E (pt) | 2004-02-27 |
DK0797987T3 (da) | 2004-02-16 |
EP0797987A1 (en) | 1997-10-01 |
KR100424931B1 (ko) | 2004-07-05 |
CN1170357A (zh) | 1998-01-14 |
NO320356B1 (no) | 2005-11-28 |
ES2210321T3 (es) | 2004-07-01 |
CN1093758C (zh) | 2002-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996019200A1 (fr) | Preparation granulaire a liberation prolongee et procede de production | |
KR0175935B1 (ko) | 가교결합된 중합체 상에 지지되고 중합체 박막으로 피복된 약제의 방출이 조절되는 치료학적 조성물 및 이의 제조방법 | |
JP4436475B2 (ja) | 固体の経口用薬剤形のための結合剤または被覆の製造に適当な水性分散液、該水性分散液の使用および再分散性粉末 | |
EP0153105A2 (en) | Diffusion coated multiple-units dosage form | |
US4970081A (en) | Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith | |
JPS6229514A (ja) | 医薬活性物質の遅延放出形粒状物及びその製造方法 | |
JP4748839B2 (ja) | シロスタゾール製剤 | |
JP2011063611A (ja) | シロスタゾール製剤 | |
WO2000024423A1 (fr) | Particules a liberation prolongee | |
JPH11130698A (ja) | アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法 | |
JPS60209518A (ja) | 貯蔵安定性を有し急速に崩壊する薬学的に活性な物質を含有する圧縮成形体及びその製造方法 | |
WO1999016448A1 (fr) | Comprime de theophylline a liberation prolongee | |
EP1722821A1 (en) | Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same | |
Patil et al. | Development and evaluation of a hot-melt coating technique for enteric coating | |
WO2008010524A1 (fr) | Procédé servant à produire des granules élémentaires sphériques contenant un médicament aisément soluble dans l'eau | |
JPH03500288A (ja) | 徐放性ニフェジピン製剤 | |
JP2006507036A (ja) | 薬剤粒子のコーティング方法 | |
AU2012208319B2 (en) | Solid molecular dispersion | |
JP3833314B2 (ja) | 発泡性組成物およびその製造方法 | |
WO2021060304A1 (ja) | 不快な味がマスクされた顆粒剤及びその製造方法 | |
WO2002034268A1 (fr) | Preparation a liberation prolongee contenant comme principe actif du trihydrochlorure de 5-acetyl-4,6-dimethyl-2-(2-(4-(2-methoxyphenyl)piperazinyl)ethylamino)pyrimidine | |
JP2012087073A (ja) | コーティング粒子の製造方法、及び該製造方法で製造されたコーティング粒子 | |
PL193028B1 (pl) | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu chlorku potasu oparte na granulkach o wysokiej zawartości składnika aktywnego oraz sposób ich wytwarzania | |
WO2017130939A1 (ja) | コーティング粒子の製造方法 | |
JPH04103525A (ja) | 難水溶性薬物の持続性製剤化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95196885.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN FI JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2207334 Country of ref document: CA Ref document number: 2207334 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970703851 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 972622 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08849457 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995940461 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995940461 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970703851 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995940461 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970703851 Country of ref document: KR |